Perrigo Valuation
Is P1RG34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of P1RG34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: P1RG34 (R$148.27) is trading below our estimate of fair value (R$317.58)
Significantly Below Fair Value: P1RG34 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for P1RG34?
Key metric: As P1RG34 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is P1RG34's PS Ratio? | |
|---|---|
| PS Ratio | 0.8x |
| Sales | US$4.39b |
| Market Cap | US$3.67b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 12.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does P1RG34's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.3x | ||
HYPE3 Hypera | 1.7x | 10.1% | R$13.0b |
OFSA3 Ouro Fino Saúde Animal Participações | 1.3x | n/a | R$1.2b |
BHC Bausch Health Companies | 0.3x | 1.5% | US$3.2b |
603707 Nanjing King-Friend Biochemical PharmaceuticalLtd | 6.1x | 25.9% | CN¥23.8b |
P1RG34 Perrigo | 0.8x | 3.4% | R$3.7b |
Price-To-Sales vs Peers: P1RG34 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2.3x).
Price to Sales Ratio vs Industry
How does P1RG34's PS Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 192 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 192 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: P1RG34 is good value based on its Price-To-Sales Ratio (0.8x) compared to the Global Pharmaceuticals industry average (2.6x).
Price to Sales Ratio vs Fair Ratio
What is P1RG34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate P1RG34's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Novartis
CHF 185.4b
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
N1VS34
CHF 60.42
7D
-0.1%
1Y
29.7%
BeiGene
US$20.5b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
B1GN34
US$45.36
7D
-2.2%
1Y
16.7%
GSK
UK£55.2b
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
G1SK34
UK£40.10
7D
-4.0%
1Y
18.9%